Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

Lars Fruergaard Jørgensen has landed the major takeover he has targeted since taking over as CEO of Novo Nordisk. Having missed out on Ablynx to Sanofi in 2018, Novo Nordisk has agreed to a $3.3 billion buyout of its RNAi partner Dicerna Pharmaceuticals as part of its search for new growth drivers.